Clinical trials: Malaria, completed
Malaria in Pregnancy
Routine Antenatal Care Versus Screening and Treatment of Malaria in Pregnancy in Rwanda
The main aim of this study is to test the primary hypothesis that the addition of intermittent screening and treatment of malaria in pregnant women (ISTp) who receive routine antenatal care (ANC) in health facilities in high…
- Trial name
- NCT03508349
- Testing
- IST
- Where
- 14 sites in Rwanda
- Volunteers
- 1,786 people, healthy volunteers welcome
- Sponsor
- Jhpiego
Malaria
Analysis of the Immune Response to the Malaria Parasite in Mali, West Africa
This study will examine the immune response to the malaria parasite at the cellular level to better understand why people achieve natural immunity to the parasite only after multiple infections and why immunity diminishes rapidly…
- Trial name
- NCT00346346
- Where
- Mali
- Volunteers
- 237 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults
Background: Malaria is caused by small germs carried by mosquitoes. People can get malaria if an infected mosquito bites them. Malaria destroys red blood cells and reduces oxygen in the blood.
- Trial name
- NCT01988636
- Testing
- PfSPZ Vaccine
- Where
- Mali
- Volunteers
- 296 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum Infection
Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults
Single site, double-blinded, randomized, placebo-controlled clinical trial of PfSPZ-CVac safety, tolerability, immunogenicity and efficacy against naturally occurring malaria in malaria-exposed Malian adults.
- Trial name
- NCT02996695
- Testing
- Artesunate, Chloroquine, PfSPZ (NF54) Challenge
- Where
- Mali
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Absolute BA and OZ439 PK Effect of Different OZ439 Dose Volumes and Cobicistat Co-administration Study
This study is an open-label, two-part study to determine the absolute bioavailability (BA) of OZ439 using simultaneous intravenous [14C]-OZ439 microdose/800mg oral dosing and to investigate the pharmacokinetics (PK) of OZ439…
- Trial name
- NCT04069221
- Testing
- Single oral dose of 800 mg OZ439, Single oral dose of 400 mg OZ439, Single oral dose of cobicistat
- Where
- Netherlands
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa
The purpose of this study is to conduct long-term surveillance for efficacy, safety and immunogenicity of the GSK Biologicals RTS,S/AS01E candidate Plasmodium falciparum malaria vaccine in infants and children in Africa following…
- Trial name
- NCT02207816
- Testing
- Blood sampling, Malaria Vaccine 257049 (MALARIA-055 PRI), Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)
- Where
- 3 sites in Burkina Faso, Kenya and 1 more
- Volunteers
- 3,084 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Malaria, Asymptomatic Parasitaemia
Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children
Malaria poses a serious burden in sub-Sahara Africa. Efforts are ongoing to scale up interventions that work. These include the use of Long Lasting Insecticidal Nets (LLIN), Intermittent Preventive Treatment in children (IPTc)…
- Trial name
- NCT04167566
- Testing
- Artemisinin Combination Therapy ACTs
- Where
- Ghana
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Noguchi Memorial Institute for Medical Research
Malaria
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1
This is a clinical trial in which healthy volunteers will be administered one or two experimental malaria vaccines. The vaccine R21 will either be administered alone or in combination with the adjuvant vaccine Matrix-M1.
- Trial name
- NCT02572388
- Testing
- R21, Matrix-M1
- Where
- 2 sites in United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Preventing the Spread of Malaria in Mali
A vaccine which interrupts malaria transmission is a critical tool to achieve the ultimate goal of eradication of this disease. Transmission blocking vaccines work by inducing antibody in vaccinated individuals that inhibits the…
- Trial name
- NCT01360112
- Where
- Mali
- Volunteers
- 816 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant
This is a study in which healthy adult volunteers will be given either an experimental Malaria vaccine or a saline control vaccine. Each volunteer will receive three vaccinations in total.
- Trial name
- NCT02925403
- Testing
- R21/Matrix-M1, Saline
- Where
- Burkina Faso
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Fever, Malaria
Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector (Aim 2)
The overall objective of this study is to evaluate the public health impact of targeted antimalarials subsidies through scale-up by determining the community-wide effects of targeting an antimalarial subsidy through a partnership…
- Trial name
- NCT02461628
- Testing
- Malaria RDT & conditional voucher for ACT from retail sector
- Where
- Kenya
- Volunteers
- 40,340 people, healthy volunteers welcome
- Sponsor
- Duke University
Acute Falciparum Malaria
Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia
Background: Malaria is an illness caused by a parasite that enters people s bodies when a mosquito bites them. It can cause fevers, headaches, body aches, and weakness. If not treated, it can make some people very ill.
- Trial name
- NCT02612545
- Testing
- Dihydroartemisinin-piperaquine (DHA-PPQ), Mefloquine (MQ)
- Where
- Cambodia
- Volunteers
- 216 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa
The purpose of this observer-blind study is to gather key efficacy, safety, and immunogenicity information on GSK's candidate malaria vaccine in infants and children.
- Trial name
- NCT00866619
- Testing
- Malaria Vaccine 257049, Meningococcal C Conjugate Vaccine, Cell-culture rabies vaccine
- Where
- 10 sites in Burkina Faso, Gabon and 5 more
- Volunteers
- 15,459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Safety and Efficacy Study of IV Artesunate to Treat Malaria
The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body.
- Trial name
- NCT00298610
- Testing
- Artesunate, Malarone
- Where
- Kenya
- Volunteers
- 30 people
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
An Efficacy Study of IV Boosting With ChAd63/MVA ME-TRAP
Plasmodium falciparum Malaria remains a major global health problem with approximately 200 million cases and 500,000 deaths worldwide annually, mostly in African infants.
- Trial name
- NCT03707353
- Testing
- ChAd63 ME-TRAP and MVA ME-TRAP vaccination
- Where
- 4 sites in United Kingdom
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Uncomplicated Vivax Malaria
IMPROV (Improving the Radical Cure of Vivax Malaria)
The main determinant of primaquine efficacy is the total dose of primaquine administered, rather than the dosing schedule. Previous trials have demonstrated that the standard low dose regimen of primaquine (3.5 mg/kg total) fails…
- Trial name
- NCT01814683
- Testing
- Primaquine
- Where
- 8 sites in Afghanistan, Ethiopia and 2 more
- Volunteers
- 2,388 people
- Sponsor
- University of Oxford
Malaria
Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites
This study is to assess the safety, tolerability, and biomarkers of protection in healthy malaria-naïve adults, who will receive bites from Anopheles stephensi mosquitoes either infected with Plasmodium falciparum Sporozoites…
- Trial name
- IMRAS (NCT01994525)
- Testing
- PfRAS, Challenge
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers
This study will be conducted in a single centre, as an open single dose two parallel cohorts design with oral doses of MMV390048 administered in healthy male and female subjects between 18 to 55 years of age.
- Trial name
- NCT02554799
- Testing
- MMV390048 formulation A, MMV390048 formulation B
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria,Falciparum
Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania
This is a dose-escalation, age de-escalation randomised double-blind controlled Phase Ib trial to assess the safety, tolerability and immunogenicity of ChAd63-RH5 administered with MVA-RH5 in a heterologous prime-boost regimen.
- Trial name
- NCT03435874
- Testing
- ChAd63 RH5, MVA RH5, Rabies Vaccine
- Where
- Tanzania
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model
This study is designed to investigate the safety and causal prophylactic efficacy of KAF156 in healthy subjects using a controlled human malaria infection model.
- Trial name
- NCT04072302
- Testing
- KAF156
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals